ImmunityBio
Prezzo: 1.69Società e modello di business
ImmunityBio is a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. Its core products include novel therapies that leverage the immune system to target tumors and viral infections. The company operates primarily in the healthcare sector, with major revenue sources stemming from research collaborations and potential future product sales. ImmunityBio is currently in the clinical trial phase for several of its therapies, which are aimed at addressing unmet medical needs in oncology and infectious disease treatment.
Profilo di investimento
The investment profile of ImmunityBio suggests it may be more suitable for growth investors, given its focus on innovative therapies and potential future market opportunities. However, the company's significant risks and recent financial performance indicate a high level of uncertainty. Investors should consider their risk tolerance and investment strategy when evaluating this stock.
Metriche fondamentali (sperimentale)
- EPS (TTM) — utile per azione degli ultimi 12 mesi, $
- -0.58 Rischio
- Ricavi QoQ — crescita dei ricavi trimestre su trimestre
- -100.0% ↓
- Sorpresa EPS
- -16.7% peggio del previsto
- Volatilità 20g
- 5.4% normal
Traccia in portafoglio
Grafico prezzo
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-05-08 15:23 | — | Vendi | scenario_deterioration |
| 2026-05-08 05:19 | Vendi | Vendi | scenario_deterioration |
| 2026-04-17 02:46 | Mantieni | Vendi | Компания демонстрирует высокую волатильность и отрицательные финансовые показатели, что указывает на значительные риски. Однако недавний рост на 51.80% за 120 дней может свидетельствовать о потенциальных возможностях для |
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2026-06-08 10:30 | Raymond James | Aggiorna | — → 5 | 1.82 |
| 2025-10-17 10:19 | Leerink Partners | Aggiorna | — → 2 | 0.8455 |
Ancora nulla